0001562180-24-004897.txt : 20240610
0001562180-24-004897.hdr.sgml : 20240610
20240610161706
ACCESSION NUMBER: 0001562180-24-004897
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240607
FILED AS OF DATE: 20240610
DATE AS OF CHANGE: 20240610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Etherington Robert Dee
CENTRAL INDEX KEY: 0001835330
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39834
FILM NUMBER: 241032945
MAIL ADDRESS:
STREET 1: 6550 SOUTH MILLROCK DRIVE
STREET 2: SUITE G50
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clene Inc.
CENTRAL INDEX KEY: 0001822791
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 852828339
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
BUSINESS PHONE: 801-676-9695
MAIL ADDRESS:
STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
FORMER COMPANY:
FORMER CONFORMED NAME: Chelsea Worldwide Inc.
DATE OF NAME CHANGE: 20200827
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-06-07
false
0001822791
Clene Inc.
CLNN
0001835330
Etherington Robert Dee
6550 SOUTH MILLROCK DRIVE
SUITE G50
SALT LAKE CITY
UT
84121
true
true
false
false
Chief Executive Officer
false
Stock Options (Right to buy)
0.37
2024-06-07
4
A
false
900000.00
0.00
A
2034-06-06
Common Stock
900000.00
900000.00
D
Stock Options (Right to buy)
0.37
2024-06-07
4
A
false
2250000.00
0.00
A
2034-06-06
Common Stock
2250000.00
2250000.00
D
This option was granted on June 7, 2024 as an option for 900,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested
This option was granted on June 7, 2024 as an option for 2,250,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs.
/s/ Jerry Miraglia POA
2024-06-10